AOWM
NKTR icon

Alpha Omega Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Alpha Omega Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12
Closed -$6K – 435
2019
Q2 		$6K Hold
12
– – ﹤0.01% 489
2019
Q1 		$6K Buy
+12
New +$7.11K ﹤0.01% 469

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpha Omega Wealth Management's NKTR Position: Q3 2019 in Review

Alpha Omega Wealth Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 12 shares — an estimated $6K sold.

Alpha Omega Wealth Management first reported a position in NKTR in Q1 2019 and held it in 2 quarters. The position peaked at $6K in Q2 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Alpha Omega Wealth Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Alpha Omega Wealth Management sold 12 Nektar Therapeutics shares in Q3 2019, an estimated $6K.
  • Alpha Omega Wealth Management first reported a position in Nektar Therapeutics in Q1 2019 and held it in 2 quarters.
  • Alpha Omega Wealth Management's Nektar Therapeutics position peaked at $6K in Q2 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Alpha Omega Wealth Management's 13F filing for Q3 2019, filed 12 Nov 2019.